ScandicNeuro Corp

09/05/2025

Scientists have built the first “artificial neuron” made from a metal–organic framework (M*F) that can behave like real brain cells in water by responding to dopamine. Unlike traditional electronic devices, this M*F neuron can carry out brain-like tasks such as learning through synaptic plasticity, sending integrate-and-fire signals, and adjusting its activity based on dopamine levels.

To demonstrate its capabilities, the team utilized the neuron to control a robotic hand. The amount of dopamine present determined how fast and how strongly the hand moved. This breakthrough brings artificial neurons a significant step closer to functioning like biological ones, opening up exciting possibilities for brain-inspired computers, smart biosensors, and advanced prosthetic devices.

This study presents the first metal-organic framework neuron with real neurotransmitter dopamine tunable spikes for neuromorphic engineering.

05/28/2025

04/30/2025

We need to improve mental health at the individual and societal levels. Despite progress in awareness and destigmatization, significant challenges remain in prevention, access to care, and support for those affected.


https://scandicneuro.com/2025/04/the-need-to-improve-mental-health/

04/28/2025

The field of mental health research is experiencing significant growth in clinical trial activity, with thousands of studies currently investigating treatments for various psychiatric conditions. Read more about the current landscape of mental health clinical trials in this report.

Clinical Trials in Mental Health: Current Landscape and Emerging Approaches Clinical Trials in Mental Health: Current Landscape and Emerging Approaches April 28, 2025 s11admin Clinical Trials in Mental Health: Current Landscape and Emerging Approaches The field of mental health research is experienc...

03/11/2025

Recent research has revealed that long-term use of common over-the-counter pain medications, such as aspirin and ibuprofen, may be associated with a 12% reduction in dementia risk. This finding comes from a study by Erasmus MC University Medical Center Rotterdam researchers, who tracked 11,745 adults over an average of 14.5 years.

The study found that long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) was linked to a decreased risk. In contrast, short-term (less than one month) and intermediate-term (one to 24 months) use showed a slight increase in risk compared to the general population. Cumulative doses without consistent use did not appear beneficial.

Scientists hypothesize that long-term use of these anti-inflammatories may help clear out the accumulation of plaques associated with dementia and Alzheimer's disease. However, it's important to note that long-term use of NSAIDs comes with potential risks, including gastrointestinal bleeding and cardiovascular issues.

Background Non-steroidal anti-inflammatory (NSAID) medication could reduce dementia risk due to anti-inflammatory and possibly amyloid-lowering properties. However, the results of observational stud...

02/14/2025

This small study suggest that vascular changes in brain trauma could trigger Alzheimer’s development. This research proposes a new understanding of neurodegenerative diseases, suggesting that vascular problems may initiate the development of amyloid-related diseases, rather than being a consequence of neuronal damage. In other words, it challenges the current view that brain cell damage comes first, arguing instead that blood vessel dysfunction could be the initial trigger.

Traumatic brain injury (TBI) often leads to impaired regulation of cerebral blood flow, which may be caused by pathological changes of the vascular smooth muscle cells (VSMCs) in the arterial wall. Moreover, these cerebrovascular changes may contribute to the development of various neurodegenerative...

01/22/2025

New research shows a 42% lifetime dementia risk for Americans over 55, higher than previous estimates. Women (48%) face more risk than men (35%) due to longer life expectancy. Risk factors include genetics, hypertension, diabetes, obesity, and inactivity.

This study highlights higher risks for Black individuals and APOE4 carriers. Researchers urge policies on heart health, education, and nutrition to slow cognitive decline. Projections suggest 1 million annual dementia cases by 2060, stressing healthcare systems.

A cohort study of over 15,000 US adults found that the lifetime risk of developing dementia from ages 55 to 95 is 42%, with the highest risk in APOE ε4 carriers, women and Black adults, and projected that approximately 1 million US adults will develop dementia annually by 2060.

12/31/2024

It is common to have problems with attention post-injury. Many times, individuals diagnosed with traumatic brain injury find themselves struggling in school or at work. Here are a few tips...

12/19/2024

Enrolling in clinical trials is being streamlined by an AI named TrialGPT. TrialGPT begins by analyzing a patient's summary, which includes important medical and demographic details. The algorithm then matches the patient with applicable clinical trials from ClinicalTrials.gov, filtering out those for which the patient does not qualify. Following this, TrialGPT clarifies how the individual meets the criteria for study enrollment. The end result is a detailed list of clinical trials ranked by eligibility and relevance, that clinicians can utilize to explore trial opportunities with their patients.

Such an algorithm may save clinicians time and accelerate clinical enrollment and research.

11/21/2024

There are concerns that mental health challenges could be used against employees in the workplace. Workers fear potential discrimination from employers if they speak up about mental health issues. Other reasons employees may hesitate to open up include worries about job security, being overlooked for promotions, damage to their reputation, privacy concerns, and a lack of support from colleagues who may not understand mental health matters. Here are five steps to enhance mental health awareness and advocacy among executives:

Many executives and organizations are still ill-equipped to support their employees through mental health challenges.

09/11/2024

Neuropsychology is increasingly integrating neuroscience techniques and advanced technologies into research and clinical practice. Read more about current trends in this article.

Integration of Neuroscience and Technology Integration of Neuroscience and Technology September 11, 2024 s11admin Integration of Neuroscience and Technology Neuropsychology is increasingly integrating neuroscience techniques and advanced technologies into research and clinical practice. Here are som...

08/28/2024

Alzheimer's disease (AD) clinical trials face significant hurdles compared to studies in other medical fields. AD clinical trials tend to have prolonged enrollment periods, higher costs, extended study duration, and the trials themselves require longer timeframes to complete. Here are some key challenges:

1. Recruitment and Retention.
-Trials often require large numbers of participants and take longer to complete compared to other therapeutic areas.
-Identifying suitable participants, especially in early stages of disease, can be difficult.
- Cognitive decline in participants can complicate ongoing participation and retention.

2. Informed Consent
- The complexity of AD trials can make informed consent difficult even for cognitively healthy individuals.
- Progressive cognitive decline in participants complicates the consent process.
- There are ethical concerns around consent capacity for those with cognitive impairment.

3. Study Design and Outcomes
- The multifactorial nature of dementia makes traditional single-intervention RCTs potentially unsuitable.
- There is inconsistency in choice and reporting of outcome measures across trials.
- Advanced statistical models are needed to properly account for disease trajectories.

4. Participant Diversity
- Many trials lack diversity and fail to represent the broader population affected by dementia.
- Innovative recruitment strategies are needed to engage underrepresented communities.

5. Biomarkers and Patient Selection
- The relevance of biomarkers in unselected older adult populations is still unclear.
- Patient selection criteria using biomarkers can limit generalizability of results.